Skip to main content
SpringerLink
Log in

Physical frailty and sarcopenia (PF&S): a point of view from the industry

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

We have observed over the last 15 years a wide debate both in the medical scientific community and in the public health arena on the definition and operationalization of frailty, typically a geriatric condition, and in particular of physical frailty linked to sarcopenia. Because physical frailty in its initial phase can still be reversed, fighting sarcopenia in elderly persons has the potential to slow or halt progressive decline towards disability and dependency. Quite recently, regulators focused attention on frailty as an indicator of biological age to be measured to characterize elderly patients before their inclusion in clinical trials. A European guidance regarding most adapted evaluation instruments of frailty is currently under public consultation. Does the regulatory initiative imply we should now consider frailty, and particularly physical frailty, primarily as an important risk factor for adverse events and poor response, or mainly as a clinical tool helping the physician to opt for one therapeutic pathway or another? Or is physical frailty above all a specific geriatric condition deserving an effective and innovative therapeutic approach with the objective to curb the incidence of its most common result, e.g., mobility disability? Pharmaceutical industry developers consider both faces of the coin very relevant. We agree with regulators that better characterization of subpopulations, not only in elderly patients, can improve the benefit risk ratio of medicines. At the same time, we believe it is in the public health interest to develop novel drugs indicated for specific geriatric conditions, like osteoporosis in the 1990s and sarcopenia today. We consider it an important therapeutic goal to effectively delay mobility disability and to extend the active, independent, and healthy life years of aging people. The “Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies” (SPRINTT) collaborative project under IMI is paving the way for adapted methodologies to study the change of physical frailty and sarcopenia in at-risk older persons and to adequately characterize the population that needs to be treated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fried LP, Tangen CM, Walston J et al. (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–56. doi:10.1093/gerona/56.3.M146

    Article  Google Scholar 

  2. Macklai NS, Spagnoli J, Junod J, Santos-Eggimann B (2013) Prospective association of the SHARE-operationalized frailty phenotype with adverse health outcomes: evidence from 60+ community-dwelling Europeans living in 11 countries. BMC Geriatr 13:3. doi:10.1186/1471-2318-13-3

    Article  PubMed  PubMed Central  Google Scholar 

  3. At J, Bryce R, Prina M et al (2015) Frailty and the prediction of dependence and mortality in low- and middle-income countries: a 10/66 population-based cohort study. BMC Med 13:138. doi:10.1186/s12916-015-0378-4

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gill TM, Gahbauer EA, Han L, Allore HG (2010) Trajectories of disability in the last year of life. N Engl J Med 362:1173–1180. doi:10.1056/NEJMoa0909087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Roubenoff R (2000) Sarcopenia: a major modifiable cause of frailty in the elderly. J Nutr Health Aging 4:140–142

    CAS  PubMed  Google Scholar 

  6. Chumlea WC, Cesari M, Evans WJ et al (2011) Sarcopenia: designing phase IIB trials. J Nutr Health Aging 15:450–455

    Article  PubMed  PubMed Central  Google Scholar 

  7. Evans W (1997) Functional and metabolic consequences of sarcopenia. J Nutr 127:998S–1003S

    Google Scholar 

  8. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. Lancet 381:752–762. doi:10.1016/S0140-6736(12)62167-9

    Article  PubMed  Google Scholar 

  9. European Medicines Agency (2015) Points to consider on frailty: evaluation instruments for baseline characterisation of clinical trial populations (draft). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/12/WC500199243.pdf. Accessed 11 Jan 2017

  10. Guralnik JM, Simonsick EM, Ferrucci L et al. (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49:M85–94. doi:10.1093/geronj/49.2.M85

    Article  Google Scholar 

  11. Studenski S, Perera S, Patel K et al (2011) Gait speed and survival in older adults. JAMA 305:50–58. doi:10.1001/jama.2010.1923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fielding RA, Vellas B, Evans WJ et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12:249–256. doi:10.1016/j.jamda.2011.01.003

    Article  PubMed  Google Scholar 

  13. European Medicines Agency (2010) Adequacy of guidance on the elderly regarding medicinal products for human use. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500049541.pdf. Accessed 11 Jan 2017

  14. European Medicines Agency (2011) EMA geriatric medicines strategy. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/02/WC500102291.pdf. Accessed 11 Jan 2017

  15. Cerreta F, Eichler HG, Rasi G (2012) Drug policy for an aging population—the European Medicines Agency’s geriatric medicines strategy. N Engl J Med 367:1972–1974. doi:10.1056/NEJMp1209034

    Article  CAS  PubMed  Google Scholar 

  16. International Conference of Harmonisation ICH E7 Studies in support of special populations: geriatrics questions & answers. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Q_As/E7_Q_As_step4.pdf. Accessed 11 Jan 2017

  17. European Commission (2011) Synthesis report on the public consultation on the European Innovation Partnership on Active and Healthy Ageing. http://ec.europa.eu/research/innovation-union/pdf/active-healthy-ageing/consultation/consultation_report.pdf. Accessed 11 Jan 2017

  18. European Commission (2011) Strategic implementation plan for the European Innovation Partnership on Active and Healthy Ageing Steering Group working document—final text adopted by the Steering Group on 2011, July 11. http://ec.europa.eu/research/innovation-union/pdf/active-healthy-ageing/steering-group/implementation_plan.pdf. Accessed 11 Jan 2017

  19. Innovative Medicines Initatives (2013) IMI 9th call for proposals: focus on frailty, use of social media to monitor drug safety, and antibiotic development. http://www.imi.europa.eu/content/press-release-imi-9th-call-proposals. Accessed 11 Jan 2017

  20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing 39:412–423. doi:10.1093/ageing/afq034

    Article  PubMed  PubMed Central  Google Scholar 

  21. Studenski SA, Peters KW, Alley DE et al (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 69:547–558. doi:10.1093/gerona/glu010

    Article  PubMed  PubMed Central  Google Scholar 

  22. Morley JE, Vellas B, Abellan van Kan G et al (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14:392–397. doi:10.1016/j.jamda.2013.03.022

    Article  PubMed  PubMed Central  Google Scholar 

  23. Dam TT, Peters KW, Fragala M et al (2014) An evidence-based comparison of operational criteria for the presence of sarcopenia. J Gerontol A Biol Sci Med Sci 69:584–590. doi:10.1093/gerona/glu013

    Article  PubMed  PubMed Central  Google Scholar 

  24. McLean RR, Shardell MD, Alley DE et al (2014) Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. J Gerontol A Biol Sci Med Sci 69:576–583. doi:10.1093/gerona/glu012

    Article  PubMed  PubMed Central  Google Scholar 

  25. Mangani I, Cesari M, Russo A et al (2008) Physical function, physical activity and recent falls. Results from the “Invecchiamento e Longevità nel Sirente (ilSIRENTE)” Study. Aging Clin Exp Res 20:234–241

    Article  PubMed  Google Scholar 

  26. Cesari M, Onder G, Zamboni V et al (2008) Physical function and self-rated health status as predictors of mortality: results from longitudinal analysis in the ilSIRENTE study. BMC Geriatr 8:34. doi:10.1186/1471-2318-8-34

    Article  PubMed  PubMed Central  Google Scholar 

  27. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R (2004) The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 52:80–85. doi:10.1111/j.1532-5415.2004.52014.x

    Article  PubMed  Google Scholar 

  28. Beaudart C, Rizzoli R, Bruyère O, Reginster JY, Biver E (2014) Sarcopenia: burden and challenges for public health. Arch Public Health 72:45. doi:10.1186/2049-3258-72-45

    Article  PubMed  PubMed Central  Google Scholar 

  29. Pahor M, Guralnik JM, Ambrosius WT et al (2014) Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA 311:2387–2396. doi:10.1001/jama.2014.5616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Cruz-Jentoft AJ, Landi F, Schneider SM et al (2014) Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 43:748–759. doi:10.1093/ageing/afu115

    Article  PubMed  PubMed Central  Google Scholar 

  31. Del Signore S, Guillet P (2015) Clinical trials in older adults: a point of view from the industry. In: Bernabei R, Ferrucci L, Marchionni N, Studenski S, Vellas B (eds) Clinical trials in older adults (Cherubini A.). Wiley, Hoboken, pp 23–43

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bluecompanion Ltd, 6 London Street, London, W2 1HR, UK

    Susanna Del Signore

  2. Global Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland

    Ronenn Roubenoff

Authors
  1. Susanna Del Signore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronenn Roubenoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanna Del Signore.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study informed consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Del Signore, S., Roubenoff, R. Physical frailty and sarcopenia (PF&S): a point of view from the industry. Aging Clin Exp Res 29, 69–74 (2017). https://doi.org/10.1007/s40520-016-0710-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-016-0710-7

Keywords

Search

Navigation